Literature DB >> 2777430

Enhancement of nonspecific resistance to bacterial infections and tumor regressions by treatment with synthetic lipid A-subunit analogs. Critical role of N- and 3-O-linked acyl groups in 4-O-phosphono-D-glucosamine derivatives.

M Nakatsuka1, Y Kumazawa, M Matsuura, J Y Homma, M Kiso, A Hasegawa.   

Abstract

Enhancement of nonspecific resistance against Pseudomonas aeruginosa infection and regression of growth of Meth A fibrosarcoma by chemically synthesized lipid A-subunit analogs, 4-O-phosphono-D-glucosamine derivatives carrying 3-O- and N-linked acyl groups, were investigated. Compounds carrying an (R)-3-hydroxytetradecanoyl (C14-OH) group at the 2-N-position with (R)-3-tetradecanoyloxytetradecanoyl [C14-O-(C14)] or (R)-3-dodecanoyloxytetradecanoyl [C14-O-(C12)] groups at the 3-O-position, termed GLA-60 or GLA-63, respectively, showed strong activity about one-tenth that of natural lipid A. The protective activity of compounds carrying an (R)-3-hexadecanoyloxytetradecanyl group instead of a C14-O-(C14) or C14-O-(C12) group was very weak. GLA-59 carrying the same acyl components as those of GLA-60 but with reversed binding sites showed significant but not so strong protective activity. The activity of compounds possessing a tetradecanoyl group instead of a C14-OH group in GLA-60 or GLA-63 was weaker than that of GLA-60 or GLA-63. Intravenous or intratumoral administration of GLA-59, GLA-60 and GLA-63 induced significant regression of Meth A fibrosarcoma in terms of tumor size, tumor weight and number of cured mice. The activity of GLA-59 was almost equivalent to that of GLA-60. None of the tested compounds exhibited significant pyrogenicity at a dose of 10 micrograms/kg in rabbits.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2777430     DOI: 10.1016/0192-0561(89)90080-5

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  8 in total

Review 1.  Progress in the synthesis and biological evaluation of lipid A and its derivatives.

Authors:  Jian Gao; Zhongwu Guo
Journal:  Med Res Rev       Date:  2017-06-16       Impact factor: 12.944

2.  Activity of monosaccharide lipid A analogues in human monocytic cells as agonists or antagonists of bacterial lipopolysaccharide.

Authors:  M Matsuura; M Kiso; A Hasegawa
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

3.  Molecular structures that influence the immunomodulatory properties of the lipid A and inner core region oligosaccharides of bacterial lipopolysaccharides.

Authors:  P J Baker; T Hraba; C E Taylor; P W Stashak; M B Fauntleroy; U Zähringer; K Takayama; T R Sievert; X Hronowski; R J Cotter
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

4.  Significant antitumor effect of a synthetic lipid A analogue, DT-5461, on murine syngeneic tumor models.

Authors:  E Kumazawa; A Tohgo; T Soga; T Kusama; Y Osada
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Biophysical characterization of triacyl monosaccharide lipid a partial structures in relation to bioactivity.

Authors:  Klaus Brandenburg; Motohiro Matsuura; Holger Heine; Mareike Müller; Makato Kiso; Hideharu Ishida; Michel H J Koch; Ulrich Seydel
Journal:  Biophys J       Date:  2002-07       Impact factor: 4.033

Review 6.  Immunopharmacology of lipid A mimetics.

Authors:  William S Bowen; Siva K Gandhapudi; Joseph P Kolb; Thomas C Mitchell
Journal:  Adv Pharmacol       Date:  2013

7.  Burkholderia mallei expresses a unique lipopolysaccharide mixture that is a potent activator of human Toll-like receptor 4 complexes.

Authors:  Paul J Brett; Mary N Burtnick; D Scott Snyder; Jeffrey G Shannon; Parastoo Azadi; Frank C Gherardini
Journal:  Mol Microbiol       Date:  2006-12-05       Impact factor: 3.501

8.  DT-5461, a new synthetic lipid A analogue, inhibits lung and liver metastasis of tumor in mice.

Authors:  K Sato; I Saiki; Y C Yoo; Y Igarashi; M Kiso; A Hasegawa; I Azuma
Journal:  Jpn J Cancer Res       Date:  1992-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.